View in EDS

EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer.

Saved in:
Bibliographic Details
Title: EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer.
Authors: Morel KL; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA., Sheahan AV; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA., Burkhart DL; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA., Baca SC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Boufaied N; Cancer Research Program, Research Institute of the McGill University Health Centre, Montréal, Canada., Liu Y; Department of Medical Biophysics, University of Toronto and Princess Margaret Cancer Center University Health Network, Toronto, Canada., Qiu X; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Cañadas I; Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA, USA., Roehle K; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Heckler M; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Calagua C; Department of Medicine, Hematology-Oncology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Ye H; Department of Pathology, University of California at Los Angeles, Los Angeles, CA, USA., Pantelidou C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Galbo P; Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY, USA., Panja S; Department of Health Informatics, Rutgers School of Health Professionals, Newark, NJ, USA., Mitrofanova A; Department of Health Informatics, Rutgers School of Health Professionals, Newark, NJ, USA.; Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA., Wilkinson S; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Whitlock NC; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Trostel SY; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Hamid AA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Kibel AS; Department of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Barbie DA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Choudhury AD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Pomerantz MM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Sweeney CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Long HW; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Einstein DJ; Hematology and Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA., Shapiro GI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Dougan SK; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Sowalsky AG; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., He HH; Department of Medical Biophysics, University of Toronto and Princess Margaret Cancer Center University Health Network, Toronto, Canada., Freedman ML; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Balk SP; Hematology and Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA., Loda M; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA., Labbé DP; Cancer Research Program, Research Institute of the McGill University Health Centre, Montréal, Canada.; Division of Urology, Department of Surgery, McGill University, Montréal, Canada., Olson BM; Departments of Hematology and Medical Oncology and Urology, Emory University School of Medicine, Atlanta, GA, USA., Ellis L; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA. Leigh.Ellis@cshs.org.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Leigh.Ellis@cshs.org.; Cancer Program, The Broad Institute of MIT and Harvard, Cambridge, MA, USA. Leigh.Ellis@cshs.org.; Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Leigh.Ellis@cshs.org.; Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA. Leigh.Ellis@cshs.org.
Source: Nature cancer [Nat Cancer] 2021 Apr; Vol. 2 (4), pp. 444-456. Date of Electronic Publication: 2021 Mar 22.
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101761119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2662-1347 (Electronic) Linking ISSN: 26621347 NLM ISO Abbreviation: Nat Cancer
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 33899001
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Morel+KL%22">Morel KL</searchLink>; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Sheahan+AV%22">Sheahan AV</searchLink>; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Burkhart+DL%22">Burkhart DL</searchLink>; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Baca+SC%22">Baca SC</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Boufaied+N%22">Boufaied N</searchLink>; Cancer Research Program, Research Institute of the McGill University Health Centre, Montréal, Canada.<br /><searchLink fieldCode="AU" term="%22Liu+Y%22">Liu Y</searchLink>; Department of Medical Biophysics, University of Toronto and Princess Margaret Cancer Center University Health Network, Toronto, Canada.<br /><searchLink fieldCode="AU" term="%22Qiu+X%22">Qiu X</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Cañadas+I%22">Cañadas I</searchLink>; Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Roehle+K%22">Roehle K</searchLink>; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Heckler+M%22">Heckler M</searchLink>; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Calagua+C%22">Calagua C</searchLink>; Department of Medicine, Hematology-Oncology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Ye+H%22">Ye H</searchLink>; Department of Pathology, University of California at Los Angeles, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Pantelidou+C%22">Pantelidou C</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Galbo+P%22">Galbo P</searchLink>; Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY, USA.<br /><searchLink fieldCode="AU" term="%22Panja+S%22">Panja S</searchLink>; Department of Health Informatics, Rutgers School of Health Professionals, Newark, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Mitrofanova+A%22">Mitrofanova A</searchLink>; Department of Health Informatics, Rutgers School of Health Professionals, Newark, NJ, USA.; Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Wilkinson+S%22">Wilkinson S</searchLink>; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Whitlock+NC%22">Whitlock NC</searchLink>; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Trostel+SY%22">Trostel SY</searchLink>; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Hamid+AA%22">Hamid AA</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Kibel+AS%22">Kibel AS</searchLink>; Department of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Barbie+DA%22">Barbie DA</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Choudhury+AD%22">Choudhury AD</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Pomerantz+MM%22">Pomerantz MM</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Sweeney+CJ%22">Sweeney CJ</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Long+HW%22">Long HW</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Einstein+DJ%22">Einstein DJ</searchLink>; Hematology and Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Shapiro+GI%22">Shapiro GI</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Dougan+SK%22">Dougan SK</searchLink>; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Sowalsky+AG%22">Sowalsky AG</searchLink>; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22He+HH%22">He HH</searchLink>; Department of Medical Biophysics, University of Toronto and Princess Margaret Cancer Center University Health Network, Toronto, Canada.<br /><searchLink fieldCode="AU" term="%22Freedman+ML%22">Freedman ML</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Balk+SP%22">Balk SP</searchLink>; Hematology and Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Loda+M%22">Loda M</searchLink>; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Labbé+DP%22">Labbé DP</searchLink>; Cancer Research Program, Research Institute of the McGill University Health Centre, Montréal, Canada.; Division of Urology, Department of Surgery, McGill University, Montréal, Canada.<br /><searchLink fieldCode="AU" term="%22Olson+BM%22">Olson BM</searchLink>; Departments of Hematology and Medical Oncology and Urology, Emory University School of Medicine, Atlanta, GA, USA.<br /><searchLink fieldCode="AU" term="%22Ellis+L%22">Ellis L</searchLink>; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA. Leigh.Ellis@cshs.org.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Leigh.Ellis@cshs.org.; Cancer Program, The Broad Institute of MIT and Harvard, Cambridge, MA, USA. Leigh.Ellis@cshs.org.; Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Leigh.Ellis@cshs.org.; Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA. Leigh.Ellis@cshs.org.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101761119%22">Nature cancer</searchLink> [Nat Cancer] 2021 Apr; Vol. 2 (4), pp. 444-456. <i>Date of Electronic Publication: </i>2021 Mar 22.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Group%22">Nature Publishing Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101761119 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2662-1347 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2226621347%22">26621347 </searchLink><i>NLM ISO Abbreviation: </i>Nat Cancer
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=33899001
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s43018-021-00185-w
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 444
    Titles:
      – TitleFull: EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Morel KL
      – PersonEntity:
          Name:
            NameFull: Sheahan AV
      – PersonEntity:
          Name:
            NameFull: Burkhart DL
      – PersonEntity:
          Name:
            NameFull: Baca SC
      – PersonEntity:
          Name:
            NameFull: Boufaied N
      – PersonEntity:
          Name:
            NameFull: Liu Y
      – PersonEntity:
          Name:
            NameFull: Qiu X
      – PersonEntity:
          Name:
            NameFull: Cañadas I
      – PersonEntity:
          Name:
            NameFull: Roehle K
      – PersonEntity:
          Name:
            NameFull: Heckler M
      – PersonEntity:
          Name:
            NameFull: Calagua C
      – PersonEntity:
          Name:
            NameFull: Ye H
      – PersonEntity:
          Name:
            NameFull: Pantelidou C
      – PersonEntity:
          Name:
            NameFull: Galbo P
      – PersonEntity:
          Name:
            NameFull: Panja S
      – PersonEntity:
          Name:
            NameFull: Mitrofanova A
      – PersonEntity:
          Name:
            NameFull: Wilkinson S
      – PersonEntity:
          Name:
            NameFull: Whitlock NC
      – PersonEntity:
          Name:
            NameFull: Trostel SY
      – PersonEntity:
          Name:
            NameFull: Hamid AA
      – PersonEntity:
          Name:
            NameFull: Kibel AS
      – PersonEntity:
          Name:
            NameFull: Barbie DA
      – PersonEntity:
          Name:
            NameFull: Choudhury AD
      – PersonEntity:
          Name:
            NameFull: Pomerantz MM
      – PersonEntity:
          Name:
            NameFull: Sweeney CJ
      – PersonEntity:
          Name:
            NameFull: Long HW
      – PersonEntity:
          Name:
            NameFull: Einstein DJ
      – PersonEntity:
          Name:
            NameFull: Shapiro GI
      – PersonEntity:
          Name:
            NameFull: Dougan SK
      – PersonEntity:
          Name:
            NameFull: Sowalsky AG
      – PersonEntity:
          Name:
            NameFull: He HH
      – PersonEntity:
          Name:
            NameFull: Freedman ML
      – PersonEntity:
          Name:
            NameFull: Balk SP
      – PersonEntity:
          Name:
            NameFull: Loda M
      – PersonEntity:
          Name:
            NameFull: Labbé DP
      – PersonEntity:
          Name:
            NameFull: Olson BM
      – PersonEntity:
          Name:
            NameFull: Ellis L
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 04
              Text: 2021 Apr
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-electronic
              Value: 2662-1347
          Numbering:
            – Type: volume
              Value: 2
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: Nature cancer
              Type: main
ResultId 1